Roy Hardiman Sells 2,692 Shares of Alumis (NASDAQ:ALMS) Stock

Alumis Inc. (NASDAQ:ALMS - Get Free Report) insider Roy Hardiman sold 2,692 shares of Alumis stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $70,988.04. Following the completion of the transaction, the insider directly owned 207,746 shares in the company, valued at approximately $5,478,262.02. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alumis Price Performance

• 3 Biopharmaceutical Stocks Bucking the Sell-Off

Shares of ALMS opened at $27.12 on Thursday. The stock has a market capitalization of $3.46 billion, a P/E ratio of -13.70 and a beta of -0.69. Alumis Inc. has a twelve month low of $3.76 and a twelve month high of $31.35. The firm has a fifty day simple moving average of $25.37 and a two-hundred day simple moving average of $25.22.

Alumis (NASDAQ:ALMS - Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. Sell-side analysts expect that Alumis Inc. will post -2.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Alumis

---

---

Several hedge funds and other institutional investors have recently modified their holdings of ALMS. Handelsbanken Fonder AB bought a new position in Alumis in the second quarter worth about $1,024,000. Stempoint Capital LP bought a new stake in Alumis during the 1st quarter valued at approximately $5,057,000. Janus Henderson Group PLC bought a new stake in Alumis during the 1st quarter valued at approximately $46,790,000. Ally Bridge Group NY LLC bought a new stake in Alumis during the 1st quarter valued at approximately $3,678,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Alumis by 600.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company's stock worth $69,000 after acquiring an additional 2,684 shares during the period.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Citigroup reaffirmed a "buy" rating on shares of Alumis in a research report on Tuesday, May 19th. Chardan Capital lifted their price objective on Alumis from $38.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, May 19th. Wells Fargo & Company boosted their target price on Alumis from $49.00 to $51.00 and gave the company an "overweight" rating in a research note on Friday, May 15th. Morgan Stanley restated an "overweight" rating and set a $39.00 target price on shares of Alumis in a report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alumis in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.30.

Check Out Our Latest Research Report on ALMS

About Alumis

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

See Also

• Five stocks we like better than Alumis
• SpaceX: Love the Company, But the Stock Is a Harder Call
• Ulta's Growth Is Real, But So Are the Risks
• BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
• Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].